OncoSil Medical
OncoSil Medical is an ASX-listed Australian medical device company that develops and commercializes the OncoSil™ Phosphorus-32 brachytherapy system for treating locally advanced unresectable pancreatic cancer, sold via hospital tenders across approved markets in Europe, the UK, and Australia.
- Company typePublic
- Founded2005
- HeadquartersNorth Sydney, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What OncoSil Medical does
OncoSil Medical Ltd (ASX:OSL) is an Australian-headquartered, single-product medical device company developing and commercializing the OncoSil™ brachytherapy system for the treatment of locally advanced unresectable pancreatic cancer (LAPC). The company is incorporated in New South Wales, listed on the ASX, and operates wholly-owned subsidiaries in the UK, Germany, US, New Zealand, and Spain to support regional commercialization across approved markets.
The OncoSil™ System consists of Phosphorus-32 microparticles (28-32 micrometer diameter beta-emitter with a 14.27-day half-life) implanted directly into pancreatic tumors under endoscopic ultrasound guidance, with 100 Gy delivered (98% within 81 days) and an average tissue range of 2.76mm. The product is indicated for use in combination with gemcitabine-based chemotherapy and has demonstrated 90.5% local disease control at 16 weeks, median overall survival of 16.1 months, and a 23.8% surgical resection rate in the PanCO pivotal study. A second delivery pathway — CT-guided percutaneous implantation — was validated through the PANCOSIL Phase 1-2 study (20 patients), expanding the procedural base beyond endoscopists to interventional radiologists.
OncoSil generates revenue through direct enterprise sales of the OncoSil device to hospitals via formal tenders (15 hospitals across Europe consistently re-ordering), supplemented by government-sponsored clinical trial revenues. Pricing is hospital-specific and not publicly disclosed. A forward revenue inflection is centered on the German G-BA Coverage with Evidence Development (CED) program — a ~40-hospital randomized trial expected to commence 1H CY26 — projected to deliver $5.6M in trial revenues plus $6.5M from commercially reimbursed treatments. The company carries regulatory approvals in the EU (CE Mark, MDR), UK, Australia (TGA, May 2026), Hong Kong, New Zealand, Switzerland, Turkey, and Israel, alongside FDA/UK/EU Breakthrough Device designations, and reported pro-forma cash of ~A$12M as of February 2026 following an A$8M capital raise.
OncoSil Medical firmographics
Firmographics- Name
- OncoSil Medical
- Legal name
- OncoSil Medical Ltd
- Website
- https://oncosil.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OncoSil Medical is an ASX-listed Australian medical device company that develops and commercializes the OncoSil™ Phosphorus-32 brachytherapy system for treating locally advanced unresectable pancreatic cancer, sold via hospital tenders across approved markets in Europe, the UK, and Australia.
- Ownership category
- akta.pro rank
OncoSil Medical industry classification
Industry- Product category
- Interventional Oncology / Brachytherapy Devices
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Digestive Oncology (GI Cancer Care) (HLAKAEAF)
- akta.pro secondary industries
- Gastrointestinal Oncology (HLAKAFAK), Medical Oncology (HLAKAFAB)
Keywords
Where OncoSil Medical is headquartered
LocationHeadquarters
- HQ city
- North Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices3 records
Markets served
OncoSil Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: OncoSil Medical generates revenue through direct commercial sales of its OncoSil brachytherapy device to hospitals and treatment centers. Hospitals procure the device through formal tender processes and departmental budget negotiations. Commercial treatments are conducted at trained hospital sites across approved markets (EU, UK, Australia, New Zealand, Hong Kong, Israel, Turkey).
- Clinical Trial Revenue: The company receives government-sponsored trial revenues, including $5.6 million in trial revenues from the German G-BA sponsored clinical trial expected to commence in 1H CY26, involving approximately 40 hospitals.
- Reimbursed Patient Treatments: Additional revenue stream of $6.5 million from commercially reimbursed patients under the German G-BA coverage with evidence development program, where treatments are conditionally reimbursed while clinical evidence is gathered.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Hospital Tender-Based Procurement |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
OncoSil Medical product offering
Product offeringCore offering
OncoSil Medical develops and commercializes the OncoSil™ System, a single-use brachytherapy device consisting of Phosphorus-32 (P-32) microparticles implanted directly into pancreatic tumors under endoscopic ultrasound guidance for the treatment of locally advanced unresectable pancreatic cancer in combination with gemcitabine-based or FOLFIRINOX chemotherapy. The device delivers targeted beta radiation (approximately 100 Gy) to the tumor while sparing surrounding healthy tissue, with both EUS-guided and CT-guided percutaneous delivery routes. The company generates revenue through direct hospital sales, clinical trial partnerships, and government-sponsored reimbursement pathways such as the German G-BA Coverage with Evidence Development program.
Product overview
OncoSil Medical offers the OncoSil™ System as its core product—a single-use brachytherapy device for treating locally advanced unresectable pancreatic cancer. The system uses Phosphorous-32 (P-32) microparticles implanted directly into pancreatic tumours via endoscopic ultrasound guidance, combined with gemcitabine-based chemotherapy. Supporting the core device are clinical resources including the OSPREY Registry (real-world observational registry), product documentation (brochures, IFU, radiation safety guidelines), and patient materials (SSCP, implant cards). The company operates as a focused medical device company with no platform architecture or additional standalone modules.
Differentiator
Problem solved
Functional benefit
Products and services
- OncoSil™ System A single-use brachytherapy device consisting of Phosphorus-32 (P-32) microparticles delivered via endoscopic ultrasound-guided implantation directly into pancreatic tumors. Indicated for treatment of locally advanced unresectable pancreatic cancer in combination with gemcitabine-based chemotherapy, with an alternative CT-guided percutaneous delivery route. The device delivers approximately 100 Gy of targeted beta radiation to the tumor with an average radiation range of 2.76mm in tissue, designed for hospitals, cancer treatment centers and interventional oncology specialists.
Quantifiable outcome
- 90.5% Local Disease Control Rate at 16 weeks (Per Protocol population, p=0.0001)
- +10 more outcomes
Companies that use OncoSil Medical
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles1 record
OncoSil Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
OncoSil Medical partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core, flagship and minor.
- CyclotekcoreManufacturing partnership for new facility in Macquarie Park, Sydney to strengthen OncoSil Medical's domestic and global supply chain capabilities. The facility is near completion and expected to support commercial scaling operations.
- Pancreatic Cancer Europe (PCE)flagshipCooperation as part of PCE's project 'Treatment Opportunities for Pancreatic Cancer.' The collaboration aims to raise awareness of innovative therapies, address treatment disparities across Europe, and improve outcomes for patients with pancreatic cancer. OncoSil will contribute expertise in innovative therapies and work with PCE to ensure the patient voice remains central.
- Cholangiocarcinoma FoundationminorExploratory collaboration discussions at ASCO GI Symposium to explore possible collaboration in increasing awareness of OncoSil technology for potential applications beyond pancreatic cancer.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
OncoSil Medical competitors and assessment
Company assessmentEmerging players
- Profound Medical: Canadian-listed image-guided interventional oncology company with TULSA-PRO and Sonalleve MR-guided ultrasound ablation systems, serving a similar physician-driven oncology practice model in solid tumor ablation.
- Nanobiotix: Clinical-stage nanotechnology company developing radioenhancers (NBTXR3) for solid tumors including pancreatic and other GI cancers. Directly comparable as a nanoparticle-based radiotherapy-enhancement approach for hard-to-treat tumors.
- HistoSonics: Emerging US-based device company commercializing histotripsy (non-invasive focused ultrasound tumor destruction) with FDA authorization and active expansion into pancreas and liver indications — competing for the interventional oncology procedure suite.
- Novocure: Commercial-stage oncology company delivering Tumor Treating Fields (TTFields) for solid tumors including pancreatic cancer (PANOVA-3 trial). Competes for the same locally advanced pancreatic cancer patient population with a non-radiation modality.
Broad incumbents
- AngioDynamics: US-listed broad interventional oncology and vascular device company with NanoKnife (irreversible electroporation) and related oncology ablation products. Competes in the interventional radiology suite across multiple indications including pancreas.
- Elekta: Swedish-listed global radiation therapy and radiosurgery incumbent offering Gamma Knife, linear accelerators, and brachytherapy afterloaders. Indirect competitor as the established radiation oncology infrastructure provider that hospitals already own.
- Varian Medical Systems (Siemens Healthineers): Global radiation oncology incumbent offering linear accelerators, Eclipse treatment planning, and SBRT technology. Head-to-head comparator in OncoSil's published comparative effectiveness analysis (22 months vs 14 months median OS for SBRT).
Direct peers
- BTG Interventional Oncology (Boston Scientific): Boston Scientific division (acquired via BTG) offering TheraSphere Y-90 glass microspheres and radiofrequency ablation systems for interventional oncology. Competes for the same interventional radiology suite workflow as OncoSil and validates the strategic value of brachytherapy assets.
- Sirtex Medical (Telix Pharmaceuticals): Australian-listed brachytherapy/radioembolization company (acquired by Telix for $1.9B) that developed SIR-Spheres Y-90 microspheres for liver cancer — closest analogue to OncoSil's P-32 brachytherapy for pancreatic cancer. OncoSil CEO Nigel Lange was formerly CEO of Sirtex and multiple executives joined from there.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
OncoSil Medical social profiles
Digital presenceOncoSil Medical compliance and trust
Trust signalCompliance7 records
OncoSil Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoSil Medical leadership team
Management profileNumber of profiles
Profiles14 records
OncoSil Medical subsidiaries and ownership
Company hierarchySubsidiaries5 records
OncoSil Medical funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoSil Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoSil Medical
What does OncoSil Medical do?
OncoSil Medical develops and commercializes the OncoSil™ System, a single-use brachytherapy device consisting of Phosphorus-32 (P-32) microparticles implanted directly into pancreatic tumors under endoscopic ultrasound guidance for the treatment of locally advanced unresectable pancreatic cancer in combination with gemcitabine-based or FOLFIRINOX chemotherapy. The device delivers targeted beta radiation (approximately 100 Gy) to the tumor while sparing surrounding healthy tissue, with both EUS-guided and CT-guided percutaneous delivery routes. The company generates revenue through direct hospital sales, clinical trial partnerships, and government-sponsored reimbursement pathways such as the German G-BA Coverage with Evidence Development program.
Is OncoSil Medical a public or private company?
OncoSil Medical is a public company. It is classified as public and is currently operating.
When was OncoSil Medical founded?
OncoSil Medical was founded in 2005. It employs 1 to 10 people.
Where is OncoSil Medical based?
OncoSil Medical is headquartered in North Sydney, Australia, in the Oceania region.
How does OncoSil Medical make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Trial Revenue and reimbursed Patient Treatments.
Who are OncoSil Medical's main competitors?
Emerging players on record are Profound Medical, Nanobiotix, HistoSonics and Novocure. Broad incumbents are AngioDynamics, Elekta and Varian Medical Systems (Siemens Healthineers). Direct peers are BTG Interventional Oncology (Boston Scientific) and Sirtex Medical (Telix Pharmaceuticals).
Does OncoSil Medical have an API?
No public API is recorded for OncoSil Medical.
What industry is OncoSil Medical in?
OncoSil Medical's product category is Interventional Oncology / Brachytherapy Devices. Its primary akta.pro industry code is HLAKAEAF, Digestive Oncology (GI Cancer Care), with a secondary code of HLAKAFAK, Gastrointestinal Oncology. Its NAICS code is 541714 and its SIC code is 3841.